Business
Inhibrx Announces Participation in Upcoming Scientific Conferences
Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences:
About this update from Inhibrx Biosciences, Inc.
[{"type":"text","content":"SAN DIEGO, Nov. 4, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, today announced it will be presenting at the following upcoming scientific conferences:","length":324,"tagName":"p"},{"type":"image","alt":"Inhibrx, Inc. logo (PRNewsfoto/Inhibrx, Inc.)","displaySize":"","headline":null,"caption":"Inhibrx, Inc. logo (PRNewsfoto/Inhibrx, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":133,"url":"https://media.zenfs.com/en/prnewswire.com/fae7441a9e255131c816a20f83e3312b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cbFWCtOSsA45e9XaqevcGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTIzNDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/fae7441a9e255131c816a20f83e3312b","width":400,"height":133}},"href":"https://mma.prnewswire.com/media/1063194/inhibrx_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":" 21st Annual Industry/Academia Precision Oncology & Radmed Symposium November 5th, 2025 – La Jolla, California ","length":118,"tagName":"p"},{"type":"text","content":" Title: DR5 Agonist Clinical Data in Chondrosarcoma, Colorectal Cancer and Ewings Sarcoma Format: Presentation Presenters: Josep Garcia, PhD, Executive Vice President, Chief Clinical Development Officer, Inhibrx; Katelyn Willis, PhD, Director, Biotherapeutics, Inhibrx Date: Wednesday, November 5th, 2025 Time: 4:45 PM Eastern Standard Time Location: The Alexandria at Torrey Pines, La Jolla, California","length":425,"tagName":"p","attribs":{}},{"type":"text","content":" Connective Tissue Oncology Society (CTOS) 2025 Annual Meeting November 12th – 15th, 2025 – Boca Raton, Florida ","length":113,"tagName":"p"},{"type":"text","content":"Title: The Tetravalent Death Receptor 5 (DR5) Agonist ozekibart (INBRX-109) in Conventional Chondrosarcoma: Results from the Randomized, Registrational, Phase 2 ChonDRAgon StudyLead Author: Robin L. Jones, MD – Medical Oncology, The Royal Marsden and Institute of Cancer ResearchFormat: PresentationDate: Friday, November 14th, 2025Time: 8:30 AM – 10:00 AM Eastern Standard TimeLocation: The Boca Raton, Boca Raton, Florida","length":443,"tagName":"p","attribs":{}},{"type":"text","content"...